DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Hueber W, Sands BE, Lewitzky S. et al; Secukinumab in Crohn's Disease Study Group.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Gut 2012;
61 (12) 1693-1700
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.